Key Highlights
- ARK Invest acquired 83,764 CoreWeave shares valued at approximately $6.9M in the Nvidia-supported AI cloud infrastructure provider
- For the first time, ARK established a direct investment position in OpenAI, purchasing nearly 349,000 shares distributed among three funds
- Additional investments included Kodiak AI for autonomous trucking, Oklo for nuclear power, DoorDash, plus genomics companies Arcturus and GeneDx
- ARK divested 745K Strata Critical Medical shares and reduced positions in Teradyne, Pinterest, and Veracyte
- ARKK has declined approximately 12% in 2024, experiencing $1.2 billion in net redemptions over the trailing twelve months
Cathie Wood’s investment firm ARK Invest demonstrated a decisive pivot toward artificial intelligence infrastructure, genomics innovation, and sustainable energy last week, deploying millions in fresh positions while scaling back several legacy holdings.
The most substantial acquisition involved CoreWeave, an Nvidia-supported cloud infrastructure provider specializing in GPU-accelerated data centers designed for artificial intelligence applications. ARK accumulated 83,764 shares over three consecutive trading sessions — March 30th, 31st, and April 1st — representing approximately $6.9 million in value at the $82 closing price.
CoreWeave, Inc. Class A Common Stock, CRWV
CoreWeave serves technology giants including Google and Microsoft as primary clients. The company disclosed fourth-quarter revenue reaching $1.57 billion in February, marking a 110% year-over-year surge. However, its forward guidance for the first quarter, ranging from $1.9 billion to $2 billion, fell short of Wall Street’s $2.29 billion consensus forecast.
Bank of America elevated CoreWeave to a buy rating in March, establishing a $100 price objective. The firm’s analysts highlighted the company’s strategic positioning within what they estimate to be a $79 billion artificial intelligence infrastructure sector.
ARK also established its inaugural direct investment in OpenAI, the organization responsible for developing ChatGPT. Three separate ARK funds — ARKF, ARKK, and ARKW — combined to purchase 348,995 shares or units via a Series C allocation. This transaction represents ARK’s first-ever direct capitalization table position in OpenAI.
Expansion into Self-Driving Logistics and Advanced Nuclear Power
ARK’s ARKQ fund secured 230,000 shares of Kodiak AI, an enterprise specializing in autonomous commercial trucking and artificial intelligence logistics solutions. The firm also obtained approximately 56,000 shares of Oklo, an emerging nuclear energy venture advancing next-generation fission reactor technology.
DoorDash represented another portfolio addition, with ARK expanding its consumer technology platform holdings through the on-demand delivery service.
Within the genomics sector, ARK’s ARKG fund purchased over 16,000 shares of Arcturus Therapeutics, a biotechnology company focused on RNA-based therapeutic development. ARK additionally acquired 39,000 shares of GeneDx, a genetic diagnostics and precision medicine provider, distributed between ARKG and ARKK.
Portfolio Reductions: Divesting Strata, Teradyne, and Pinterest Stakes
Regarding divestments, ARK’s most significant exit by volume involved Strata Critical Medical. The firm liquidated 745,000 shares representing roughly $3 million in value.
ARK also decreased its allocation in Veracyte, a molecular diagnostics company, and scaled back semiconductor testing specialist Teradyne. Additional reductions affected Pinterest, Discovery, and Japanese digital platform LY Corp.
Wood has articulated expectations for a “great acceleration” in worldwide economic expansion fueled by artificial intelligence advancement. She projects AI training expenses are declining 75% annually while inference computing costs decrease between 85% and 98% each year.
ARKK has fallen approximately 12% year-to-date, contrasted with a 3.8% decline in the S&P 500. The flagship fund has recorded $1.2 billion in net redemptions throughout the past twelve months.
CoreWeave concluded trading at $82.24 on April 2nd and has appreciated 15% year-to-date.


